Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis
|
|
- Noah Gray
- 6 years ago
- Views:
Transcription
1 Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis Authors: Phan Thai (phanvuongkhacthai@yahoo.com) Dang Ha (hadtm@oucru.org) Nguyen Hanh (annanguyenhanh@gmail.com) jeremy day (jday@oucru.org) sarah dunstan (sarah.dunstan@unimelb.edu.au) nguyen nhu (nhuntq@yahoo.com.vn) vo kiet (kietvs@oucru.org) Nguyan Lan (nguyenhuulan1965@yahoo.com.vn) ngueyn dung (bshuydung@yahoo.com) nguyen lan (ngoclan@hcm.fpt.vn) thuong thuong (thuongntt@oucru.org) nguyen Lan (ngoclan0456@yahoo.com) Pham Lieu (lieuphamthithuy@yahoo.com) nguyen thi hong (hongquang0701@yahoo.com) dao diep (daocongdiep@yahoo.com) Nguyen thanh (kimthanh0459@gmail.com) nguyen hoi (nguyenvanhoi99a@gmail.com) nguyen van nghia (bsnguyennghia@yahoo.com.vn) Truong dai (truongngocdai@gmail.com.vn) hoang minh (bsminhsg@yahoo.com.vn) nguyen thom (pklaoq8@gmail.com) jeremy farrar (jfarrar@oucru.org) Maxine Caws (mcaws@hotmail.com) Version: 1 Date: 13 Aug 2017
2 Author s response to reviews: BMC Infectious Diseases Response to reviewers. Reviewer 1. This is a good manuscript that adds to the growing literature on the poorer outcome of INHresistant TB, in this study 12.6% by sputum smear criteria during therapy, but an additional ~16% failed during 2 year follow-up using culture. We thank the reviewer for his comments on the value of the contribution of the manuscript to the literature on INH-resistant TB treatment outcomes. 1) How about prior treatment, extensiveness of disease, cavitation, site of disease, malnutrition - all the usual risk factors for poor outcome or relapse that we think about? All Patients recruited to the study were new TB patients (no prior history of disease). This stated on line Regarding site of disease, patients were all pulmonary TB cases as stated on line Patients were also all HIV-negative as stated on line For clarity we have modified the relevant sentence in the methods section of the abstract (line 87-89): Between December 2008 and June ,090 consecutive HIV-negative adults ( 18 years of age) with new smear positive pulmonary TB presenting at participating district TB units in Ho Chi Minh City were recruited. We do not have data on extent of cavitation or malnutrition which we agree are all factors contributing to poor outcome for TB disease in general. 2) Should we test for Beijing in INH-R disease as a matter of routine and treat them differently? This study is not sufficient evidence to recommend testing for Beijing lineage as a routine measure for patients with INH-R disease but does suggest further investigation is warranted and genotyping should be included in randomized clinical trials for TB treatment to establish if all lineages respond well to any novel regimen. This observational cohort was treated with the 8-
3 month regimen, with an HE continuation phase which is no longer recommended by WHO and is being phased out by Vietnam, therefore it would not be appropriate to make routine treatment recommendations based on this data, however we believe the data is of value in the literature on INH-R TB. A consideration of lineage in patient management may be warranted if studies with current and novel regimens confirm a higher risk of failure/relapse for Beijing lineage INH-R strains. 3) Additional patients were detected with unfavorable outcome during follow-up - but this additional rate needs to be compared against INH-S controls to interpret it. This is mentioned as a limitation in the discussion but it is significant. If relapse rates in INH-S patients are also high, then one is mainly left with a high failure rate of INH-R during therapy and intensive monitoring during that phase would be targeted. By contrast if relapse of INH-R is particularly high, then perhaps longer durations would be targeted. This is discussed as the reviewer notes in the discussion section, lines 368 to 371. Although two year follow-up data on the INH-S cohort was not available due to funding limitations, the existing literature on relapse in INH-S TB evaluated by culture at 2 years shows that INH-S TB does not have these high rates of unfavourable outcome. We have added a relevant reference reporting the 30-month follow-up of the IUATLD landmark study A which evaluated the 8- month regimen. The rate of unfavourable outcome for fully susceptible TB treated with the 8- month regimen was 10% in this study. Nunn AJ, Jindani A, Enarson DA, Study Ai: Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis. Int J Tuberc Lung Dis 2011, 15(6): Regardless of the comparison with INH-S TB, the extremely high rate of unfavourable outcome in the INH-R cohort clearly shows that this 8-month regimen is unacceptable for the treatment of INH-R TB and that the majority of these failures occur after the treatment completion evaluation at 8-months and so would not be apparent under standard programmatic conditions. 4) It appears there was substantial discordance between MODS and MGIT. Would be helpful to describe this correlation in a paragraph, even if poor. It is understandable to consider MGIT as
4 the gold-standard for simplicity sake, but this method is not perfect and reporting of discordances is underrepresented in the literature which perpetuates poor gold-standards. The dramatic scale-up of programmatic rapid molecular testing for TB using the genexpert system has reduced the application of MODS testing as a diagnostic for TB. Evaluation of the discrepancy between MODS and MGIT testing is not the aim of this manuscript and would require a separate report conforming to STAARD guidelines to present in full. MODS was the initial rapid test used to identify INH-R patients for enrolment into the study cohort. Due to a change in the international recommendation for the critical concentration for INH_R MODS testing in the middle of the study, we used MGIT testing which is a well-validated reference standard, to confirm INH resistance in patients included for the INH-R analysis at completion of the study. We recognise this is not an ideal situation, however the retrospective MGIT testing was the most appropriate way to ensure consistent classification of the isolate drug susceptibility profile, in light of the issues with MODS classification which became apparent internationally during the study period. 5) Table 4 would be helpful to include the (n) for the risk factors on the left. Some risk factors may have been very rare, leading to imprecision with the OR estimates. We have added the (n) for risk factors for table 4. The 95% CI which is presented gives the precision of the OR estimates. Reviewer two. 1) The definition of "isoniazid-resistance" is very elusive. Isoniazid resistance is defined in the context of this study in the abstract, lines Isoniazid resistance is considered any isoniazid resistant isolates that are susceptible to rifampicin. Resistance to isoniazid and rifampicin is classified as multi-drug resistant TB (MDR TB) in line with WHO definitions. The term isoniazid monoresistant is not applicable as the isolates classified as isoniazid resistant here may also be susceptible to streptomycin or ethambutol, or
5 both these drugs. The susceptiblilty patterns of isolates from patients in the cohort is shown in table one. We have added the definition of INH-R to the background (lines ) and methods sections for clarity (lines 241 to 244). This definition is consistent with the literature on TB and WHO definitions. 2) What would be very useful is a clearly composed manuscript where MODS/MGIT is performed upon diagnosis and cases of isoniazid monoresistance are followed-up and compared to MDR and those without any resistance. Please reformat the manuscript to describe this story. We fully agree with the reviewer it would be ideal if MGIT had also been performed at diagnosis. However, this was not the original study design because MGIT susceptibility results take longer than MODS and we originally planned the study to ensure fast identification of INH- R for recruitment into the INH-R cohort. However, due to the change in international standard MODS critical concentration in the middle of the study, we performed MGIT DST retrospectively to standardize the catagorisation of drug susceptibility profile for all patients analysed in the study. It was obviously not possible to implement MGIT testing at diagnosis retrospectively when the problems with MODS testing for INH-R became apparent after international systematic review of available literature. This is described in methods (lines ). See also response to reviewer one, point (4) above. 3) What would be very useful is a clearly composed manuscript where MODS/MGIT is performed upon diagnosis and cases of isoniazid monoresistance are followed-up and compared to MDR and those without any resistance. MODS was performed upon diagnosis. Isoniazid monoresistance is relatively rare in Vietnam and therefore analysis of an INH monoresistant cohort would be small. Isoniazid resistance usually occurs with streptomycin and/or ethambutol resistance in this setting. Therefore the
6 analysis of INH monoresistance is less relevant here than the analysis of INH-resistance without rifampicin resistance [isoniazid resistant isolates susceptible to rifampicin +/- resistance to streptomycin/ethambutol]. This is consistent with the literature on TB, where INH resistant TB is considered to be any resistant to INH which is rifampicin susceptible (ie. Not MDR TB). 4) For ease of reviewing please use continuous line numbers. Due to the line numbers restarting on each page I have simply referred to the page below. Line numbers have been changed to continuous. The revised continuous line numbers are referenced in this response. 5) No need to capitalise isoniazid in the title Capitalization of isoniazid in the title has been removed. 6) when was MODS performed? MODS was performed at diagnosis. This is stated in the methods lines ) What was the relationship between MGIT and MODS? Were the 239 people with I-R bacteria also detected via MODS?
7 As for reviewer one, point (4) above. MODS was performed at diagnosis to identify patients for recruitment to the INH-R cohort. Due to changes in the international standard definition these were later confirmed as INH-R by MGIT testing. The 239 people analysed in the INH-R cohort were therefore INH-R by both MODS and MGIT testing. 8) Are these purely isoniazid monoresistant? The classification of INH-R is addressed in reviewer two response (1) and (4) above. It is not INH monoresistance. 9) what does unfavourable mean? You should not need to delve into the manuscript to understand what criteria you are using. Definition of unfavourable outcome is given in methods section on statistical analysis (lines ). This is a standard WHO definition used in the literature on assessment of TB treatment outcome and clinical trials for TB. We did not consider it necessary to define in the introduction but are happy to add if the editor considers it necessary. Favourable outcomes are the WHO programmatic outcome categories cure and treatment completion. Unfavourable outcomes are the WHO outcome categories death, and treatment failed. For further information see the WHO standard guidelines for the programmatic management of tuberculosis. 10) As above - what is standard WHO monitoring This is also defined in the methods lines This is standard WHO programmatic TB treatment evaluation used by all national TB Programmes using smear microscopy to assess
8 response to treatment. For the 8-month regimen, this is sputum smear evaluation at months 2,5 and 8. Again, we are happy to add to the introduction if requested by the editor but consider it more appropriate to the methods section. 11) Ensure WHO is spelled out correctly (organization) We have corrected spelling of WHO and thank the reviewer for noting the typo. 12) Ref 8 link is dead. We have updated the WHO link to TB treatment guidelines: 13) Explain what standard WHO monitoring is As above for point (10). 14) what blood testing is done? This has been corrected to more detailed follow-up and testing. We thank the reviewer for noting the typo.
9 15) What is CRF? We have added the definition of CRF-( Case Report Form) and apologize for the omission. A CRF is used to collect patient information in clinical studies. 16) Does this means MODS was only performed at 5 and 8 months? When on treatment? If baseline MODS was not performed then I don't see what can be concluded from any of this study as any resistance is likely to have been de novo. MODS culture was performed at diagnosis as described in the recruitment section of the methods, lines ) What did the other 4.9% of patients receive? Why were these individualised regimens used? The remaining 4.9% of patients received individualized regimens as described in the subsequent paragraph (lines ). This was determined by the treating clinician. This was an observational cohort study under programmatic conditions and not a treatment trial, therefore the study protocol did not dictate treatment which was determined by the treating clinician, usually in accordance with the Vietnamese NTP guidelines. 18) Again, when was MODS performed? Why was there no culture in such a significant proportion of supposedly smear-positive people? How were MODS -ve and indeterminate managed? Did INH-R and MDR patients receive appropriate treatment following MODS testing?
10 MODS was performed at diagnosis, as for point (6) above. This is stated in the methods lines Culture is not routinely performed for TB patients in Vietnam. This is the case for most high burden countries. Culture is routinely only performed for retreatment patients. MODS was not an approved diagnostic test to determine treatment for the Vietnamese NTP at the time of the study and was used as a research tool here, to identify patients for recruitment to the INH-R cohort for intensified follow-up. Patients who were smear positive for TB were treated and managed according to the Vietnamese NTP guidelines and treatment decisions were made by the treating clinician. Follow-up of MDR cases was beyond the scope of this manuscript. 19) Lower down on the page the 324 MODS cases becomes 328. Which is correct? The number of INH-R MODS cases has been corrected to 324, apologies and we thank the reviewer for noting this error. 20) It is very confusing that MGIT DST is available on 1710 and it is not clear when this was performed, why MODS was performed, how one led to the other, etc. This has already been addressed in reviewer one point (4) and reviewer two point (2). The timing of MODS testing is given in the methods section MGIT DST was retrospectively performed on the cultures isolated at diagnosis. A number of cultures failed to revive or were contaminated to subculture and therefore MGIT DST results were available on 1710 cases. 21) Results should actually be presented in the results section, not purely refer to the tables. We have described the key findings in the results section in the interests of manuscript length and referred to the tables for detailed presentation of all the statistical comparisons made. We are happy to extend this text if the editor feels it is necessary.
11 22) Where does the figure 457 come from? Describe in more detail the comparisons made for the mutation significance tests. Were promoter mutations, etc. present and in what numbers - all of these figures should be provided. How are INDO strains more likely to be wild type when supposedly the comparisons were being made among resistant strains - what then was the resistance mutation? The mutations at katg 315 and inha -15 were analysed for this study, the major mutations conferring ING resistance in Mtb. The occurrence of Mtb isolates phenotypically resistant to INH without any known mutations for INH resistance is well documented, hence wild-type INH-R isolates are well described in the literature. We have rephrased the sentence to clarify that the use of wild-type here refers to the sites tested (katg and inha). We have added the number mutated in katg and inha. 457 is the number of isolates resistant to INH by MGIT with a molecular genotype result available. As this analysis of lineage with molecular genotype did not include outcome, it contained a greater number of patients, not only those recruited into the INH-R intensified follow-up cohort. 23) Pg 16 - The figure 239 then appears. Where did this come from as it doesn't fit anywhere with what is shown in table patients were included in the INH-R cohort with intensified follow-up of outcomes and received the standardized regimens. This is stated at the start of the paragraph (lines ): 239 patients in the extended INH study had confirmed INH resistant, RIF susceptible isolates by MGIT DST, received a standardised regimen and were therefore analysed for risk factors associated with unfavourable outcome. 24) Pg 17 - Don't quote 12.6% as a percentage of all INH-R cases, quote it as a percentage of the ones with unfavourable outcomes.
12 12.6% here is not a percentage of those with unfavourable outcomes as suggested by the reviewer, it is the % of all INH-R cases with unfavourable outcomes by WHO evaluation- the original sentence is correct. 25) Rather than persistence, the relationship of resistance with Beijing lineage is most likely a hypermutable state. Would be worth exploring this further as it is the only significant finding in this study and therefore needs to be placed within the context of other studies. We agree this finding warrants further exploration. While the hypermutable state has been proposed as a theory for the increased prevalence of resistance among Beijing lineage strains in some settings, the current evidence is weak and it remains one of several possible explanations for the characteristics attributed to the Beijing genotype. We disagree that there is sufficient evidence to say that the higher rates of unfavourable outcome documented here are attributable to a hyper-mutable state of the Beijing lineage strains, but we agree this requires further investigation to understand the underlying mechanisms responsible. The true explanation is likely multi-factorial and a combination of many characteristics which allow greater persistence and emergence of resistance of bacilli despite standard treatment. 26) Pg 18 - You note that katg has previously been associated with higher MICs than the promoter mutation but then have not shown this to not be the case in the results section Yes, the katg315 mutation has been associated with higher MIC in previous studies but was not in this study. 27) Pg 19 - The fact that it is so difficult to know the timeframe of when susceptibility testing is carried out and the (actually high) likelihood that much of this may be reinfection, I believe that this is a very major limitation of the study. MIRU-24 would go some way to help distinguish
13 whether this is the case or not. The "genotypes" in this study are extremely broad and not based on current gold standards. The timeframe of testing has been addressed in multiple points above. Final classification of resistance was based on the initial diagnostic culture, performed retrospectively by MGIT DST. The lineage classification used here is the current gold standard and consistent with the current understanding of Mtb phylogeny and is appropriate for this study. A more discrepant classification, such as MIRU-24 is appropriate to a transmission study but not here as this study was looking at the association of bacterial lineage with outcome. It is highly unlikely that these unfavourable outcomes are reinfection as this is a low HIV prevalence setting and the annual infection rate is too low. This is in contrast to high HIV prevalence settings in sub-saharan Africa. If reinfection occurred from the original, presumably untreated, index patient within two years, MIRU-24 analysis would not detect this as a reinfection because the genotype would be identical. 28) Table 2: Is INH Resistant TB monoresistant? INH monoresistant TB is Mtb that is only resistant to isoniazid and susceptible to all other TB drugs. This is a standard definition. INH resistant TB in table 2 is not INH monoresistant TB, it is TB resistant to INH. 29) Table 2: What is going on in the District 1 cell that just contains 0.? This has been corrected to [ ], we thank the reviewer for noticing this omission of this 95% CI.
14 30) Table 3: What comparisons are actually being tested in this table The footnote to table 3 (lines ) explains the comparison made. Each lineage is compared with all other isolates to examine the association between lineage and drug resistance. 31) Table 4: Why adjust for resistance to streptomycin and ethambutol? Adjustment has been made for strep and ethambutol resistance to these additional drugs may confound the analysis.
Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.
Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical
More informationTitle: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.
Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationThe treatment of patients with initial isoniazid resistance
The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011 Outline Background
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationDrug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER
Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationOnline Annexes (2-4)
Online Annexes (2-4) to WHO Policy update: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin THE END TB STRATEGY Online Annexes (2-4) to WHO Policy update:
More informationResearch Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal
Hindawi International Scholarly Research Notices Volume 2017, Article ID 1635780, 5 pages https://doi.org/10.1155/2017/1635780 Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant
More informationOnline Annexes (5-8)
2016 Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs 1 Contents: Annex 5: GRADE summary of findings
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014
TB Nurse Case Management San Antonio, Texas April 1 3, 2014 Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationAnnex 1. Methods for evidence reviews and modelling
WHO/HTM/TB/2011.6a. Methods for evidence reviews and modelling Questions for the 2011 update of the Guidelines for the programmatic management of drug-resistant tuberculosis (for Outcomes please see Table
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationThe shorter regimen for MDR-TB: evidence and pitfalls
The shorter regimen for MDR-TB: evidence and pitfalls Helen Cox 10 November 2017 What is the shortened regimen? Current conventional regimen (SA): Intensive Phase (at least 6 months): PZA / (EMB) / Kana
More informationTransmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University
Transmission of MDR/XDR Tuberculosis in Shanghai Qian Gao Shanghai Medical College Fudan University Drug Resistant TB in China The Highest DR-TB Burden Country New TB cases/year Cases with any DR MDR XDR
More informationWhat is drug resistance? Musings of a clinician
What is drug resistance? Musings of a clinician William Burman MD Denver Public Health Tuberculosis Trials Consortium Financial disclosures Tibotec (developer of TMC207 and several antiretroviral drugs)
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationNew frontiers: Innovation and Access
8th Regional TB Symposium Tashkent, Uzbekistan Prof. L.N. Chernousova Central Tuberculosis Research Institute (CTRI) Ministry of Health of the Republic of Uzbekistan 28 February 1 March, 2019 1970 1975
More informationTB infection control: overview and importance
TB infection control: overview and importance John Ferguson, Newcastle, NSW Infectious Diseases & Microbiology jferguson@hnehealth.nsw.gov.au Goroka Hospital, September 2014 Patterns of TB disease Latent
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationHost genotypes, inflammatory response and outcome of TBM Vietnam
Host genotypes, inflammatory response and outcome of TBM Vietnam Nguyen T.T. Thuong Oxford University Clinical Research Unit Ho Chi Minh City, Vietnam Tuberculous Meningitis (TBM) Diagnosis remains difficult
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationLatest developments in WHO estimates of TB disease burden
Latest developments in WHO estimates of TB disease burden WHO Global Task Force on TB Impact Measurement meeting Glion, 1-4 May 2018 Philippe Glaziou, Katherine Floyd 1 Contents Introduction 3 1. Recommendations
More informationMycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline
Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana
More informationRamesh P. M.*, Saravanan M.
International Journal of Advances in Medicine Ramesh PM et al. Int J Adv Med. 2018 Jun;5(3):561-565 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20181663
More informationDST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?
DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps? Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and
More informationSTREAM Trial Update. I.D. Rusen, The Union CPTR Meeting April 5, 2016 Washington, DC
STREAM Trial Update I.D. Rusen, The Union CPTR Meeting April 5, 2016 Washington, DC Financial Disclosure The Union receives funding from various sources to implement the STREAM Trial: Stage 1 USAID (TREAT
More informationOnline Annexes (5-8)
Online Annexes (5-8) to WHO Policy guidance: The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs THE END TB STRATEGY Online Annexes (5-8) to WHO
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationThe Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida
The Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida Calin B. Chiribau, 1 M-C. Rowlinson, 1 S.Crowe, 1 B. Jones, 1
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms Revised June 2018 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient
More informationTitle: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection
Author's response to reviews Title: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection Authors: Adithya Cattamanchi (acattamanchi@medsfgh.ucsf.edu)
More informationNATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis
NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis Patients registered during quarter* of 20 Name of area No.# Name of the Reporter Signature:
More informationPrinciple of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos
Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases
More informationTransmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos
Transmissibility, virulence and fitness of resistant strains of M. tuberculosis CHIANG Chen-Yuan MD, MPH, DrPhilos Transmissibility, Virulence and Fitness of resistant strains of M. tuberculosis For infectious
More informationInternational Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007
TB Along the US/Mexico Border El Paso, Texas August 22-23, 2007 International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 Barbara J Seaworth MD Medical Director Heartland National
More informationPredicting outcomes and drug resistance with standardised treatment of active tuberculosis
Eur Respir J 21; 36: 87 877 DOI: 1.1183/931936.15179 CopyrightßERS 21 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis O. Oxlade*,#, K. Schwartzman*,#, M. Pai*,#,
More informationEvaluation of Xpert MTB/RIF and MODS assay for the diagnosis of pediatric tuberculosis
Nhu et al. BMC Infectious Diseases 2013, 13:31 RESEARCH ARTICLE Open Access Evaluation of Xpert MTB/RIF and MODS assay for the diagnosis of pediatric tuberculosis Nguyen Thi Quynh Nhu 1, Dang Thi Minh
More informationTitle: What 'outliers' tell us about missed opportunities for TB control: a cross-sectional study of patients in Mumbai, India
Author's response to reviews Title: What 'outliers' tell us about missed opportunities for TB control: a cross-sectional study of patients in Authors: Anagha Pradhan (anp1002004@yahoo.com) Karina Kielmann
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationTB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012
TB Nurse Case Management San Antonio, Texas March 7-9, 2012 Diagnosis of TB: Laboratory Ken Jost Wednesday March 7, 2012 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationInformation Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis
Information Note WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis In order to ensure that the upcoming comprehensive revision of WHO policies on treatment
More informationGLI model TB diagnostic algorithms
GLI model TB diagnostic algorithms GLI model TB diagnostic algorithms March 2017 Contents Acknowledgements Abbreviations v vi Background 1 Algorithm 1: Preferred algorithm for universal patient access
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationMulti-country surveillance project on fluoroquinolones and PZA resistance
Multi-country surveillance project on fluoroquinolones and PZA resistance Matteo Zignol CPTR Rapid DST 2014 Workshop September 22-23, 2014 Washington DC, US Objectives of the FQLs and PZA surveillance
More informationCertainty assessment of patients Effect Certainty Importance. a standardised 9 month shorter MDR-TB regimen. e f
Author(s): STREAM Stage 1 Trial investigators reported for the Guideline Development Group for the WHO treatment guidelines on MDR/RR-TB, 2018 update (6 July 2018) - FINAL RESULTS Question: PICO 1. In
More informationEffectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) M Bonnet, M Bastard, P du Cros, K Atadjan, K Kimenye, S Khurkhumal, A Hayrapetyan, A Telnov, C Hewison, F Varaine
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationWhen good genes go bad
When good genes go bad Dr Kessendri Reddy NHLS Tygerberg Hospital Division of Clinical Microbiology Fakulteit Geneeskunde en Gesondheidswetenskappe Faculty of Medicine and Health Sciences Overview Cases
More informationGlobal Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics
Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationHarmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis
Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis Grace Lin, MS. Research Scientist grace.lin@cdph.ca.gov APHL 8 th TB Lab Conference San Diego 8-19-13 Harmonizing? There
More informationMeeting report on IMPACT TB workshop Vietnam 31 st March 2017 Ha Noi www.impacttbproject.org Table of Contents Executive Summary... 3 Objectives of the meeting... 4 Participants and organisations... 5
More informationSirturo: a new treatment against multidrug resistant tuberculosis
Sirturo: a new treatment against multidrug resistant tuberculosis TB is an on-going problem WHO estimated incidence of new TB cases 2009 Global Tuberculosis Control: WHO report 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html
More information11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction
SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationKritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen
Kritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen Hans L Rieder Union Internationale Contre la Tuberculose et
More informationPyrosequencing Experience from Mumbai, India. Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India
Pyrosequencing Experience from Mumbai, India Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India Mumbai maximum city Slow Fast 1-2 D With increasing drug resistance, DST is vital
More informationStacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona
Role of the Laboratory in TB Diagnosis Stacy White, PhD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Stacy White, PhD has the following disclosures
More informationLaboratory Diagnosis for MDR TB
Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationStudy of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan
Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationTB Laboratory for Nurses
TB Laboratory for Nurses Shea Rabley, RN, MN Consultant Mayo Clinic Center for Tuberculosis 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Participants will be able to: 1. Name 2 safety
More informationCharacteristics of Mycobacterium
Mycobacterium Characteristics of Mycobacterium Very thin, rod shape. Culture: Aerobic, need high levels of oxygen to grow. Very slow in grow compared to other bacteria (colonies may be visible in up to
More informationMSF Field Research. Diagnosis and management of drug-resistant tuberculosis. South African adults. Hughes, J; Osman, M
MSF Field Research Diagnosis and management of drug-resistant tuberculosis in South African adults Authors Citation DOI Publisher Journal Rights Hughes, J; Osman, M Diagnosis and management of drug-resistant
More informationFrances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS
The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationOriginal Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
Int J Clin Exp Pathol 2017;10(4):4847-4851 www.ijcep.com /ISSN:1936-2625/IJCEP0045802 Original Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
More informationDrug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye
Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case
More informationTB the basics. (Dr) Margaret (DHA) and John (INZ)
TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2
More informationSensitivity and specificity of an index for the diagnosis of TB meningitis in patients in an urban teaching hospital in Malawi
Tropical Medicine and International Health doi:10.1111/j.1365-3156.2008.02109.x volume 13 no 8 pp 1042 1046 august 2008 Sensitivity and specificity of an index for the diagnosis of TB in in an urban teaching
More informationHow Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008
How Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008 Today s Outline 1) Global spread of Mtb Comparative genomics Phylogeny 2) Transmission of drug-resistant Mtb Fitness assays Molecular epidemiology
More informationChallenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam
Hoang et al. BMC Public Health (2015) 15:980 DOI 10.1186/s12889-015-2338-5 RESEARCH ARTICLE Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam Open Access Thuy
More informationManagement of Drug-resistant Tuberculosis (DR-TB)
Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a
More informationA household survey on screening practices of household contacts of smear positive tuberculosis patients in Vietnam
Thanh et al. BMC Public Health 2014, 14:713 RESEARCH ARTICLE Open Access A household survey on screening practices of household contacts of smear positive tuberculosis patients in Vietnam Thuy Hoang Thi
More informationIMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE
Original Article IMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE P. G. Gopi, R. Subramani, V. Chandrasekaran, T. Santha and P. R. Narayanan
More informationCMH Working Paper Series
CMH Working Paper Series Paper No. WG5 : 8 Title Interventions to reduce tuberculosis mortality and transmission in low and middle-income countries: effectiveness, cost-effectiveness, and constraints to
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 5, Issue 2 Newsletter Date: February 2013 APSR EDUCATION PUBLICATION Inside this issue: Tuberculosis Multidrug-resistant pulmonary tuberculosis treatment regimens and patient
More informationHow best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
More informationINTENSIFIED TB CASE FINDING
INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities
More informationAuthor's response to reviews
Author's response to reviews Title: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold
More informationOverview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing
Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing 1. Essentials for the Mycobacteriology Laboratory: Promoting Quality Practices 1.1 Overview: Mycobacterial Culture, Identification,
More informationThe Impact of Isoniazid Preventive Therapy and Antiretroviral Therapy on Tuberculosis Incidence in Children Living with HIV in Vietnam
The Impact of Isoniazid Preventive Therapy and Antiretroviral Therapy on Tuberculosis Incidence in Children Living with HIV in Vietnam K.H. Truong 1, H.T. Nguyen 2, X. Gao 3, Y. Hu 2,3, J. Harwell 2,3,
More informationContact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan
Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan 17 th Annual Conference, The Union-North American Region, Vancouver, Canada. 28 February 2013 Farhana Amanullah Director
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationTitle: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study
Author's response to reviews Title: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study Authors: Delia Goletti (d.goletti@tiscali.it)
More informationAnnex 2. GRADE glossary and summary of evidence tables
WHO/HTM/TB/2011.6b. GRADE glossary and summary of evidence tables GRADE glossary Absolute effect The absolute measure of intervention effects is the difference between the baseline risk of an outcome (for
More informationResearch Article Characteristics and Treatment Outcomes of Retreatment Tuberculosis Patients in Benin
Tuberculosis Research and Treatment Volume 2016, Article ID 1468631, 7 pages http://dx.doi.org/10.1155/2016/1468631 Research Article Characteristics and Treatment Outcomes of Retreatment Tuberculosis Patients
More informationDetection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 1543-1549 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.185
More information